Works by Mikhael, Joseph R.

Results: 26
    1
    2
    3

    Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00794-x
    By:
    • Fonseca, Rodrigo;
    • Arribas, Mariano;
    • Wiedmeier-Nutor, Julia E.;
    • Kusne, Yael N.;
    • González Vélez, Miguel;
    • Kosiorek, Heidi E.;
    • Butterfield, Richard J.;
    • Kirsch, Ilan R.;
    • Mikhael, Joseph R.;
    • Stewart, A. Keith;
    • Reeder, Craig;
    • Larsen, Jeremy;
    • Bergsagel, P. Leif;
    • Fonseca, Rafael
    Publication type:
    Article
    4

    Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00794-x
    By:
    • Fonseca, Rodrigo;
    • Arribas, Mariano;
    • Wiedmeier-Nutor, Julia E.;
    • Kusne, Yael N.;
    • González Vélez, Miguel;
    • Kosiorek, Heidi E.;
    • Butterfield, Richard J.;
    • Kirsch, Ilan R.;
    • Mikhael, Joseph R.;
    • Stewart, A. Keith;
    • Reeder, Craig;
    • Larsen, Jeremy;
    • Bergsagel, P. Leif;
    • Fonseca, Rafael
    Publication type:
    Article
    5
    6
    7
    8

    Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.

    Published in:
    American Journal of Hematology, 2017, v. 92, n. 5, p. 448, doi. 10.1002/ajh.24671
    By:
    • Bennani, N. Nora;
    • LaPlant, Betsy R.;
    • Ansell, Stephen M.;
    • Habermann, Thomas. M.;
    • Inwards, David J.;
    • Micallef, Ivana N.;
    • Johnston, Patrick B.;
    • Porrata, Luis F.;
    • Colgan, Joseph P.;
    • Markovic, Svetomir N.;
    • Nowakowski, Grzegorz S.;
    • Macon, William R.;
    • Reeder, Craig B.;
    • Mikhael, Joseph R.;
    • Northfelt, Donald W.;
    • Ghobrial, Irene M.;
    • Witzig, Thomas E.
    Publication type:
    Article
    9

    A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.

    Published in:
    American Journal of Hematology, 2017, v. 92, n. 5, p. 467, doi. 10.1002/ajh.24693
    By:
    • Rosenthal, Allison;
    • Dueck, Amylou C.;
    • Ansell, Stephen;
    • Gano, Katherine;
    • Conley, Christopher;
    • Nowakowski, Grzegorz S.;
    • Camoriano, John;
    • Leis, Jose F.;
    • Mikhael, Joseph R.;
    • Keith Stewart, A.;
    • Inwards, David;
    • Dingli, David;
    • Kumar, Shaji;
    • Noel, Pierre;
    • Gertz, Morie;
    • Porrata, Luis;
    • Russell, Stephen;
    • Colgan, Joseph;
    • Fonseca, Rafael;
    • Habermann, Thomas M.
    Publication type:
    Article
    10

    Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial.

    Published in:
    American Journal of Hematology, 2011, v. 86, n. 8, p. 640, doi. 10.1002/ajh.22053
    By:
    • Kumar, Shaji K.;
    • Lacy, Martha Q.;
    • Hayman, Suzanne R.;
    • Stewart, Keith;
    • Buadi, Francis K.;
    • Allred, Jacob;
    • Laumann, Kristina;
    • Greipp, Philip R.;
    • Lust, John A.;
    • Gertz, Morie A.;
    • Zeldenrust, Steven R.;
    • Bergsagel, P. Leif;
    • Reeder, Craig B.;
    • Witzig, Thomas E.;
    • Fonseca, Rafael;
    • Russell, Stephen J.;
    • Mikhael, Joseph R.;
    • Dingli, David;
    • Rajkumar, S. Vincent;
    • Dispenzieri, Angela
    Publication type:
    Article
    11

    A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.

    Published in:
    2018
    By:
    • Padrnos, Leslie;
    • Ernst, Brenda;
    • Dueck, Amylou C.;
    • Kosiorek, Heidi E.;
    • Ginos, Brenda F.;
    • Toro, Angela;
    • Johnston, Patrick B.;
    • Habermann, Thomas M.;
    • Leis, Jose F.;
    • Mikhael, Joseph R.;
    • Nowakowski, Grzegorz S.;
    • Colgan, Joseph;
    • Porrata, Luis;
    • Ansell, Stephen M.;
    • Witzig, Thomas E.;
    • Reeder, Craig
    Publication type:
    journal article
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22

    AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.

    Published in:
    British Journal of Haematology, 2014, v. 164, n. 3, p. 352, doi. 10.1111/bjh.12633
    By:
    • Paulus, Aneel;
    • Chitta, Kasyapa;
    • Akhtar, Sharoon;
    • Personett, David;
    • Miller, Kena C.;
    • Thompson, Kevin J.;
    • Carr, Jennifer;
    • Kumar, Shaji;
    • Roy, Vivek;
    • Ansell, Stephen M.;
    • Mikhael, Joseph R.;
    • Dispenzieri, Angela;
    • Reeder, Craig B.;
    • Rivera, Candido E.;
    • Foran, James;
    • Chanan‐Khan, Asher
    Publication type:
    Article
    23
    24

    A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.

    Published in:
    British Journal of Haematology, 2012, v. 156, n. 3, p. 326, doi. 10.1111/j.1365-2141.2011.08949.x
    By:
    • Khan, Meaghan L.;
    • Reeder, Craig B.;
    • Kumar, Shaji K.;
    • Lacy, Marthy Q.;
    • Reece, Donna E.;
    • Dispenzieri, Angela;
    • Gertz, Morie A.;
    • Greipp, Phillip;
    • Hayman, Suzanne;
    • Zeldenhurst, Steven;
    • Dingli, David;
    • Lust, John;
    • Russell, Stephen;
    • Laumann, Kristina M.;
    • Mikhael, Joseph R.;
    • Leif Bergsagel, P.;
    • Fonseca, Rafael;
    • Vincent Rajkumar, S.;
    • Keith Stewart, A.
    Publication type:
    Article
    25
    26